condit
may
present
similarli
concomitantli
aecopd
pulmonari
embol
pneumonia
cardiac
ischemia
congest
heart
failur
entiti
must
identifi
promptli
howev
clinic
perspect
pursuit
etiolog
usual
relev
approach
acut
treatment
may
valu
prevent
subsequ
episod
improv
chronic
symptom
treatment
condit
need
consid
evalu
aecopd
present
aecopd
nonspecif
must
distinguish
lifethreaten
cardiopulmonari
condit
includ
congest
heart
failur
cardiac
ischemia
pneumonia
pulmonari
embol
last
condit
receiv
attent
recent
literatur
analysi
publish
suggest
preval
pulmonari
embol
among
patient
hospit
acut
copd
although
limit
studi
analysi
make
clinic
interpret
applic
find
difficult
test
support
guidelin
initi
approach
aecopd
determin
physiolog
sever
respiratori
distress
evalu
concomit
contributori
cardiac
pulmonari
condit
make
accur
triag
decis
care
addit
histori
physic
examin
basic
laboratori
studi
electrocardiogram
follow
diagnost
intervent
may
consid
descend
order
chest
radiograph
recommend
exist
guidelin
evalu
aecopd
base
data
observ
studi
patient
present
presum
aecopd
patient
chest
film
suggest
chang
treatment
altern
concomit
diagnosi
eg
heart
failur
pneumonia
arteri
blood
ga
analysi
perform
patient
assess
degre
hypoxemia
hypercarbia
assess
indic
noninvas
ventil
assess
effect
supplement
oxygen
therapi
test
influenza
virus
may
season
appropri
could
affect
choic
treatment
addit
sputum
cultur
gener
indic
lack
specif
find
chronic
colon
copd
patient
airway
ubiqu
contamin
likewis
spirometri
dubiou
benefit
limit
data
show
clinic
outcom
correl
spirometri
acut
set
evidencebas
guidelin
sever
indic
suffici
accur
distinguish
patient
safe
treat
outpati
benefit
hospit
therefor
decis
admit
patient
hospit
clinic
decis
initi
clinic
determin
assess
actual
immin
respiratori
failur
endorgan
instabl
could
prompt
assist
ventil
admiss
intens
care
american
thorac
societi
publish
guidelin
guid
decis
hospit
patient
aecopd
highrisk
comorbid
includ
pneumonia
cardiac
arrhythmia
heart
failur
diabet
mellitu
renal
liver
failur
inadequ
respons
symptom
outpati
manag
mark
increas
dyspnea
inabl
eat
sleep
owe
symptom
worsen
hypoxemia
worsen
hypercapnia
chang
mental
statu
inabl
care
oneself
lack
home
support
uncertain
diagnosi
numer
guidelin
avail
guid
therapi
aecopd
hospit
patient
princip
therapi
major
patient
includ
bronchodil
corticosteroid
antibiot
oxygen
therapi
earli
consider
noninvas
positivepressur
ventil
nippv
addit
prophylaxi
venou
thromboembol
vte
evalu
influenza
pneumococc
vaccin
appropri
evid
base
shortact
bronchodil
allevi
dyspnea
improv
airflow
obstruct
aecopd
either
b
adrenerg
agonist
anticholinerg
agent
may
administ
set
type
agent
act
rapidli
may
administ
nebul
form
meter
dose
inhal
mdi
compel
evid
nebul
superior
mdi
although
administr
nebul
anxiou
dyspneic
patient
may
easier
better
toler
systemat
review
methylxanthin
bronchodil
aecopd
suggest
trend
toward
shorter
length
stay
lo
hospit
also
symptomat
relaps
week
advers
effect
nausea
palpit
arrhythmia
anticholinerg
ipratropium
bromid
also
effect
aecopd
combin
therapi
anticholinerg
agent
consist
shown
benefit
aecopd
systemat
review
conclud
evid
support
simultan
therapi
suggest
superior
b
agonist
anticholinerg
evid
support
choic
dose
bronchodil
optim
dose
interv
bronchodil
establish
formal
studi
albuterol
common
b
agonist
administ
via
nebul
dose
increas
dose
mg
shown
improv
lung
function
reduc
hospit
lo
even
data
support
practic
system
corticosteroid
treatment
adopt
standard
part
treatment
aecopd
decis
base
presum
clinic
similar
copd
asthma
recognit
import
role
system
corticosteroid
play
revers
airway
inflamm
asthma
howev
time
becam
clear
inflammatori
process
involv
diseas
differ
clinic
effect
glucocorticoid
copd
much
smaller
asthma
largest
random
control
trial
address
question
trial
sponsor
veteran
administr
va
publish
patient
hospit
aecopd
random
receiv
system
glucocorticoid
treatment
placebo
treat
broadspectrum
antibiot
bronchodil
primari
outcom
treatment
failur
defin
follow
death
caus
need
intubationmechan
ventil
readmiss
copd
intensif
pharmacolog
treatment
result
show
patient
treat
system
glucocorticoid
experienc
lower
rate
treatment
failur
mostli
relat
need
intensif
treatment
placebo
group
mainli
ad
glucocorticoid
therefor
benefit
ad
system
corticosteroid
earli
primarili
one
would
avoid
add
later
howev
steroid
group
also
shorter
lo
signific
improv
fev
day
enrol
also
significantli
higher
rate
hyperglycemia
requir
medic
therapi
comparison
control
group
investig
conclud
glucocorticoid
offer
modest
benefit
patient
hospit
copd
cost
signific
hyperglycemia
patient
sever
studi
metaanalys
examin
use
glucocorticoid
treatment
aecopd
part
support
similar
conclus
cochran
collabor
metaanalysi
found
patient
aecopd
treat
system
glucocorticoid
experienc
significantli
fewer
treatment
failur
odd
ratio
confid
interv
ci
treat
placebo
fig
base
data
patient
aecopd
would
need
receiv
steroid
prevent
treatment
failur
anoth
metaanalysi
found
patient
aecopd
treat
system
glucocorticoid
experienc
shorter
hospit
lo
day
shorter
ci
studi
also
found
steroid
associ
improv
fev
decreas
breathless
improv
blood
ga
abnorm
popul
howev
steroid
never
demonstr
mortal
benefit
aecopd
studi
glucocorticoid
aecopd
perform
noncrit
ill
popul
howev
recent
studi
patient
intens
care
unit
demonstr
decreas
rate
noninvas
ventil
failur
shorter
durat
mechan
ventil
treat
glucocorticoid
compar
placebo
suggest
benefit
treatment
extend
popul
well
risk
associ
glucocorticoid
treatment
aecopd
use
system
glucocorticoid
patient
popul
without
risk
advers
effect
drug
includ
psychosi
osteoporosi
hyperglycemia
muscl
wast
insomnia
increas
appetiteweight
gain
chronic
obstruct
pulmonari
diseas
one
everi
patient
treat
glucocorticoid
experi
advers
effect
common
hyperglycemia
everi
patient
overal
system
glucocorticoid
modest
signific
treatment
benefit
aecopd
complic
rel
frequent
often
manag
complic
everi
patient
treat
treatment
failur
prevent
hospit
durat
reduc
nearli
medic
complic
occur
hyperglycemia
common
global
initi
chronic
obstruct
lung
diseas
gold
guidelin
recommend
glucocorticoid
prescrib
hospit
patient
aecopd
author
concur
recommend
patient
although
clinic
judgment
requir
situat
wherebi
riskbenefit
ratio
alter
eg
clinic
mild
exacerb
coupl
high
risk
side
effect
glucocorticoid
optim
glucocorticoid
dose
durat
rout
deliveri
treatment
patient
hospit
aecopd
question
dose
durat
especi
import
mani
advers
effect
glucocorticoid
use
includ
psychiatr
effect
osteoporosi
hyperglycemia
correl
degre
exposur
glucocorticoid
medic
therefor
prudent
use
lowest
dose
shortest
cours
medic
achiev
desir
benefit
unfortun
clinic
trial
directli
compar
efficaci
high
medium
lowdos
regimen
dose
rang
mg
methylprednisolon
daili
mg
solumedrol
everi
hour
follow
taper
dose
shown
benefici
effect
larg
observ
studi
examin
data
almost
patient
find
differ
outcom
includ
initi
mechan
ventil
mortal
readmiss
patient
treat
highdos
equival
mgd
prednison
versu
lowdos
equival
mgd
prednison
glucocorticoid
first
day
admiss
data
suggest
high
initi
dose
glucocorticoid
advantag
optim
dose
glucocorticoid
aecopd
remain
uncertain
gold
guidelin
recommend
mg
oral
prednisolon
daili
optim
durat
treatment
also
unknown
base
avail
evid
va
studi
discuss
earlier
compar
cours
treatment
cours
treatment
found
benefit
longer
cours
small
studi
hospit
patient
demonstr
cours
glucocorticoid
result
better
improv
spirometr
measur
dyspnea
exert
paco
level
cours
cochran
collabor
metaanalysi
abl
identifi
studi
compar
durat
corticosteroid
treatment
aecopd
publish
abstract
therefor
avail
data
allow
firm
conclus
regard
optim
durat
glucocorticoid
treatment
aecopd
gold
guidelin
recommend
day
evid
steroid
prepar
better
anoth
use
equival
dose
also
clear
rout
administr
eg
intraven
vs
chronic
obstruct
pulmonari
diseas
oral
import
oral
glucocorticoid
highli
bioavail
intraven
administr
medic
reserv
patient
unabl
take
medic
mouth
suspicion
oral
medic
might
absorb
reason
larg
observ
studi
discuss
earlier
abl
show
differ
outcom
compar
oral
intraven
treatment
gold
guidelin
recommend
standard
cours
mg
oral
prednisolon
daili
day
glucocorticoid
gradual
taper
prescrib
aecopd
discontinu
abruptli
question
well
studi
appli
mani
diseas
treat
brief
burst
glucocorticoid
medic
although
even
brief
cours
glucocorticoid
suppress
pituitaryadren
axi
suppress
like
clinic
signific
appear
short
durat
therefor
glucocorticoid
regimen
aecopd
compar
one
recommend
requir
taper
abruptli
discontinu
end
cours
bacteri
infect
frequent
identifi
precipit
acut
exacerb
copd
implic
case
common
moraxella
catarrhali
haemophilu
influenza
streptococcu
pneumonia
pseudomona
aeruginosa
import
pathogen
patient
sever
copd
fev
predict
atyp
bacteria
chlamydophila
legionella
mycoplasma
uncommon
pathogen
staphylococcu
aureu
frequent
isol
patient
acut
exacerb
copd
acquisit
new
bacteri
strain
correl
exacerb
copd
viral
infect
also
frequent
contributor
acut
exacerb
copd
rhinoviru
frequent
isol
season
influenza
parainfluenza
coronaviru
also
frequent
contributor
half
acut
exacerb
copd
trigger
bacteri
infect
patient
hospit
acut
exacerb
copd
treat
antibiot
exact
indic
patient
select
remain
controversi
mani
previou
studi
differenti
acut
chronic
bronchiti
lack
adequ
assess
pneumonia
placebo
control
major
guidelin
differ
slightli
recommend
initi
antibiot
therapi
acut
exacerb
copd
gold
guidelin
explicitli
address
decis
initi
antibiot
recent
updat
advoc
use
antibiot
acut
exacerb
copd
scenario
patient
present
cardin
symptom
aecopd
increas
sputum
purul
increas
sputum
volum
worsen
dyspnea
patient
present
increas
sputum
purul
plu
either
increas
sputum
volum
worsen
dyspnea
sever
exacerb
requir
mechan
ventil
either
nippv
invas
endotrach
ventil
american
thorac
societi
differ
slightli
recommend
suggest
antibiot
initi
hospit
patient
chang
either
sputum
purul
sputum
volum
practic
speak
major
patient
hospit
acut
exacerb
copd
increas
either
sputum
purul
sputum
volum
treatment
antibiot
would
indic
import
differenti
acut
exacerb
copd
bacteri
pneumonia
atyp
bacteri
infect
less
frequent
trigger
copd
exacerb
mani
common
antibiot
regimen
acut
exacerb
copd
provid
adequ
coverag
atyp
pathogen
base
find
major
acut
exacerb
copd
trigger
infect
antibiot
use
treatment
aecopd
decad
one
earliest
trial
antibiot
aecopd
show
rel
increas
rate
treatment
success
decreas
risk
deterior
ambulatori
patient
treat
antibiot
sinc
landmark
articl
numer
publish
studi
shown
decreas
mortal
durat
mechan
ventil
readmiss
treatment
failur
earli
metaanalysi
random
trial
antibiot
exacerb
copd
show
small
signific
benefit
antibiot
benefit
antibiot
seem
greatest
patient
sever
exacerb
copd
appropri
antibiot
treatment
acut
exacerb
copd
antibiot
select
patient
acut
exacerb
copd
requir
integr
understand
microbiolog
pathogenesi
copd
exacerb
patientspecif
risk
factor
resist
pathogen
knowledg
local
microbiolog
resist
pattern
gener
sever
exacerb
copd
requir
broader
empir
antibiot
coverag
moder
exacerb
copd
patient
without
risk
factor
p
aeruginosa
monotherapi
macrolid
respiratori
fluoroquinolon
secondor
thirdgener
cephalosporin
frequent
recommend
recent
metaanalysi
random
control
trial
compar
macrolid
antibiot
fluoroquinolon
antibiot
show
differ
rate
treatment
failur
group
lower
incid
side
effect
macrolid
antibiot
patient
age
year
older
sever
copd
exacerb
per
year
receiv
recent
antibiot
therapi
within
past
day
risk
resist
pathogen
increas
broader
coverag
sputum
cultur
suggest
patient
virul
rapid
acquisit
antibiot
resist
p
aeruginosa
particularli
import
pathogen
acut
exacerb
copd
risk
factor
p
aeruginosa
detail
box
patient
present
one
risk
factor
coverag
antibiot
known
activ
p
aeruginosa
antipseudomon
blactam
fluoroquinolon
aminoglycosid
indic
select
appropri
antibiot
guid
local
resist
pattern
patient
prior
sputum
cultur
sensit
avail
long
antibiot
continu
acut
exacerb
copd
ideal
durat
antibiot
therapi
acut
exacerb
copd
unknown
gold
guidelin
recommend
day
antibiot
therapi
recommend
base
consensu
opinion
howev
interpret
caution
recent
metaanalysi
compar
day
day
therapi
show
differ
outcom
fewer
advers
event
shorter
durat
therapi
practic
durat
antibiot
therapi
adjust
base
initi
respons
therapi
sever
underli
diseas
longer
durat
reserv
patient
delay
clinic
respons
sever
airflow
obstruct
baselin
reason
close
followup
discharg
hospit
particularli
import
patient
acut
exacerb
copd
longterm
antibiot
prophylaxi
prevent
acut
exacerb
copd
controversi
larg
metaanalysi
show
reduct
acut
exacerb
longterm
prophylaxi
mean
day
disabl
avoid
per
month
treatment
two
recent
trial
renew
interest
antibiot
prophylaxi
particularli
highrisk
patient
first
show
decreas
risk
exacerb
patient
treat
puls
moxifloxacin
mg
daili
day
everi
week
greater
effect
purul
sputum
baselin
second
demonstr
reduct
exacerb
increas
time
first
exacerb
month
use
regimen
azithromycin
mg
daili
patient
high
risk
exacerb
howev
regimen
increas
risk
hear
loss
longterm
prophylaxi
consid
patient
frequent
exacerb
despit
optim
medic
therapi
care
weigh
risk
increas
antibiot
resist
advers
drug
reaction
indic
noninvas
positivepressur
ventil
acut
exacerb
copd
noninvas
positivepressur
ventil
nippv
help
facilit
alveolar
ga
exchang
potenti
improv
ventil
oxygen
patient
acut
respiratori
failur
indic
initi
nippv
aecopd
primarili
patient
acut
hypercarb
respiratori
failur
gold
guidelin
suggest
use
nippv
patient
either
respiratori
acidosi
arteri
ph
andor
arteri
carbon
dioxid
tension
paco
mm
hg
sever
dyspnea
sign
respiratori
muscl
fatigu
increas
work
breath
use
accessori
respiratori
muscl
paradox
abdomin
movement
retract
intercost
muscl
indic
nippv
patient
acut
exacerb
copd
hypoxem
respiratori
failur
less
clear
intern
consensu
confer
intens
care
medicin
recommend
nippv
consid
patient
hypoxem
respiratori
failur
specif
recommend
subset
patient
acut
exacerb
copd
hypox
respiratori
failur
intern
consensu
confer
statement
noninvas
posit
pressur
ventil
defin
contraind
nippv
includ
cardiac
respiratori
arrest
acut
sever
organ
failur
hemodynam
instabl
sever
encephalopathi
sever
upper
gastrointestin
hemorrhag
recent
esophag
anastomosi
facial
surgeri
trauma
deform
upper
airway
obstruct
inabl
patient
protect
airway
high
aspir
risk
inabl
clear
oropharyng
secret
mani
patient
sever
sever
copd
advanc
direct
outlin
clear
limit
invas
mechan
ventil
prudent
initi
discuss
limit
particularli
appli
noninvas
ventil
time
admiss
hospit
patient
acut
exacerb
copd
potenti
benefit
nippv
avoid
need
invas
mechan
ventil
primari
risk
nippv
aecopd
aspir
gastric
oropharyng
content
unlik
invas
mechan
ventil
nippv
mechan
prevent
aspir
gastric
content
addit
posit
airway
pressur
creat
pressur
gradient
facilit
passag
oropharyng
gastric
content
lower
airway
complic
nippv
includ
facial
irrit
gastric
distens
sinus
conjunctiv
irrit
improp
mask
seal
patient
discomfort
numer
prospect
random
trial
demonstr
benefit
nippv
acut
exacerb
copd
reduc
need
invas
mechan
ventil
chronic
obstruct
pulmonari
diseas
improv
respiratori
mechan
reduc
inhospit
mortal
larg
metaanalysi
show
reduct
inhospit
mortal
less
need
endotrach
intub
less
treatment
failur
compar
standard
medic
care
benefit
nippv
much
less
clear
patient
mild
moder
copd
exacerb
mode
nippv
select
patient
acut
exacerb
copd
clinician
sever
choic
mode
initi
nippv
patient
acut
exacerb
copd
assist
control
pressur
support
ventil
proport
assist
ventil
shown
improv
respiratori
physiolog
decreas
respiratori
distress
patient
acut
exacerb
copd
bilevel
posit
airway
pressur
provid
higher
inspiratori
pressur
coupl
lower
expiratori
pressur
gener
well
toler
patient
littl
evid
support
one
mode
nippv
anoth
initi
nippv
patient
monitor
close
sign
clinic
improv
repeat
arteri
blood
ga
analysi
obtain
within
hour
initi
improv
ph
paco
hour
predict
success
nippv
certain
patient
nippv
poorli
toler
worsen
respiratori
distress
patient
must
identifi
earli
facilit
expediti
transit
altern
mode
ventil
patient
copd
high
incid
cardiovascular
diseas
coronari
arteri
diseas
common
popul
probabl
relat
share
risk
factor
tobacco
smoke
one
studi
popul
patient
copd
found
cardiovascular
diseas
common
caus
lung
diseas
hospit
death
supraventricular
arrhythmia
includ
atrial
fibril
multifoc
atrial
tachycardia
also
common
patient
aecopd
possibl
relat
hypercarbia
hypoxemia
hemodynam
chang
occur
condit
side
effect
medic
use
treatment
methylxanthin
medic
eg
theophyllin
glucocorticoid
associ
hospitalist
often
must
simultan
manag
aecopd
acut
cardiovascular
diseas
manag
aecopd
hospit
hospitalist
must
awar
cardiovascular
comorbid
includ
underli
coronari
arteri
diseas
acut
cardiac
ischemia
atrial
arrhythmia
acut
heart
lung
diseas
occur
togeth
special
consider
aris
first
urgenc
control
patient
lung
diseas
increas
set
concomit
cardiovascular
diseas
second
medic
use
treatment
may
need
alter
treat
acut
cardiac
pulmonari
problem
simultan
case
coronari
arteri
diseas
attent
hypoxemia
critic
maxim
myocardi
oxygen
deliveri
moreov
case
atrial
arrhythmia
revers
hypoxemia
acidosi
caus
underli
lung
diseas
may
elimin
arrhythmia
altogeth
howev
treatment
atrial
fibril
cardiac
ischemia
simultan
treatment
aecopd
sometim
requir
use
medic
opposit
effect
especi
case
adrenerg
antiadrenerg
medic
specif
bblocker
often
use
control
heart
rate
atrial
fibril
myocardi
demand
acut
cardiac
ischemia
wherea
bagonist
typic
use
combat
bronchospasm
aecopd
therefor
hospitalist
may
encount
situat
wherebi
bagonist
bantagonist
might
indic
although
seemingli
contradictori
theori
effect
bagonist
might
undesir
set
cardiac
diseas
despit
rel
select
receptor
caus
tachycardia
especi
use
high
dose
howev
signific
associ
arrhythmia
sinu
tachycardia
clearli
demonstr
clinician
balanc
risk
tachycardia
benefit
bagonist
treatment
acut
set
littl
evid
guid
decis
may
prudent
use
nonbagonist
bronchodil
eg
anticholinerg
preferenti
situat
tachycardia
cardiac
ischemia
major
concern
american
colleg
cardiologyamerican
heart
associ
accaha
guidelin
manag
atrial
fibril
recommend
bagonist
avoid
patient
bronchospast
ill
develop
atrial
fibril
howev
insuffici
evid
harm
bagonist
therapi
set
preclud
use
thought
essenti
patient
care
nonselect
bblocker
caus
signific
bronchoconstrict
pulmonari
effect
seen
bblocker
one
metaanalysi
examin
trial
cardioselect
bblocker
prescrib
patient
copd
examin
effect
spirometr
measur
symptom
effect
bronchodil
medic
patient
given
bblocker
studi
conclud
effect
studi
paramet
bblocker
medic
appear
entir
safe
patient
copd
note
patient
studi
copd
sever
diseas
howev
none
studi
target
patient
aecopd
metaanalysi
offer
strong
evid
pulmonari
effect
bblocker
minim
common
practic
withhold
medic
patient
stabl
copd
unwarr
addit
larg
observ
studi
suggest
bblocker
may
even
benefici
patient
copd
first
examin
larg
popul
copd
patient
demonstr
lower
risk
death
acut
exacerb
copd
associ
use
bblocker
second
studi
examin
copd
patient
hospit
copd
exacerb
demonstr
lower
risk
death
associ
use
bblocker
hospit
although
studi
challeng
convent
wisdom
bblocker
chronic
obstruct
pulmonari
diseas
avoid
copd
interpret
caution
observ
studi
almost
certainli
taint
select
bia
eg
patient
exhibit
sever
bronchoconstrict
least
like
treat
bblocker
although
studi
use
statist
method
correct
bia
method
imperfect
conclus
base
must
acknowledg
methodolog
limit
avail
studi
clearli
delin
acut
ill
patient
activ
bronchoconstrict
might
react
initi
bblocker
medic
may
therefor
prudent
use
altern
medic
eg
nondihydropyridin
calciumchannel
blocker
digoxin
control
heart
rate
set
acut
bronchoconstrict
strong
indic
bblocker
medic
acc
aha
guidelin
manag
atrial
fibril
recommend
avoid
bblocker
treatment
patient
atrial
fibril
also
bronchospast
lung
diseas
howev
strong
indic
bblocker
medic
eg
cardiac
ischemia
altern
medic
provid
desir
effect
appropri
prescrib
bblocker
even
face
acut
bronchoconstrict
methylxanthin
medic
eg
theophyllin
aminophyllin
also
avoid
patient
atrial
arrhythmia
known
precipit
arrhythmia
multifoc
atrial
tachycardia
mat
arrhythmia
appear
secondari
abnorm
automat
trigger
atrial
activ
rhythm
recogn
distinct
pwave
morpholog
observ
electrocardiogram
demonstr
ventricular
rate
greater
beat
per
minut
mat
much
less
common
atrial
fibril
close
associ
copd
patient
mat
signific
underli
lung
diseas
nearli
patient
acut
respiratori
failur
demonstr
arrhythmia
hypoxemia
hypercarbia
hemodynam
chang
relat
aecopd
treatment
methyxanthin
may
contribut
develop
rhythm
howev
mat
also
associ
varieti
clinic
condit
includ
heart
diseas
hypokalemia
hypomagnesemia
mat
typic
transient
rhythm
often
resolv
treatment
underli
diseas
patient
mat
set
aecopd
therefor
treat
aggress
lung
diseas
methyxanthin
medic
avoid
hypokalemia
hypomagnesemia
correct
small
studi
intraven
administr
magnesium
often
slow
termin
rhythm
even
patient
normal
serum
concentr
magnesium
might
consid
earli
intervent
patient
without
contraind
mat
persist
problemat
pharmacolog
treatment
also
prescrib
goal
slow
andor
termin
rhythm
verapamil
metoprolol
effect
achiev
goal
small
compar
trial
suggest
metoprolol
may
effect
two
use
bblock
medic
patient
aecopd
bronchospasm
discuss
note
cardiovers
shown
effect
treat
arrhythmia
atrioventricular
nodal
ablat
use
control
rhythm
refractori
case
hart
et
al
addit
venou
thromboembol
prophylaxi
smoke
cessat
emphas
appropri
vaccin
provid
smoke
cessat
probabl
import
prevent
health
intervent
deliv
smoke
patient
although
tobacco
abus
depend
chronic
diseas
wide
believ
recurr
brief
counsel
intervent
increas
likelihood
cessat
hospit
creat
unusu
set
circumst
wherebi
patient
temporarili
allow
smoke
direct
contact
health
care
worker
provid
educ
support
addit
mani
hospit
patient
treat
nicotin
replac
therapi
curb
symptom
nicotin
withdraw
therefor
hospit
perfect
opportun
encourag
smoke
cessat
systemat
review
studi
smoke
cessat
hospit
patient
demonstr
counsel
intervent
hospit
result
improv
cessat
rate
month
ci
intervent
continu
phone
facetofac
contact
month
discharg
counsel
effort
limit
hospit
stay
persist
less
month
discharg
appear
improv
cessat
rate
review
also
found
nicotin
replac
therapi
ad
counsel
result
trend
toward
improv
cessat
rate
ci
therefor
hospitalist
recommend
smoke
cessat
smoker
hospit
also
reason
use
nicotin
replac
therapi
hospit
treat
nicotin
withdraw
symptom
continu
discharg
patient
express
intent
quit
inpati
smokingcess
consult
servic
avail
hospitalist
also
use
servic
benefit
patient
unit
state
center
diseas
control
prevent
recommend
annual
influenza
vaccin
pneumococc
vaccin
patient
copd
patient
popul
influenza
vaccin
result
fewer
copd
exacerb
may
also
lead
decreas
hospit
death
pneumococc
vaccin
shown
reduc
complic
appear
reduc
invas
pneumococc
diseas
gener
popul
patient
effort
improv
vaccin
rate
organ
led
develop
standingord
vaccin
program
allow
hospit
facil
provid
vaccin
appropri
patient
without
individu
physician
order
program
result
improv
vaccin
rate
hospit
patient
commonli
receiv
vaccin
organ
although
often
accomplish
without
direct
input
hospitalist
hospitalist
practic
hospit
without
standingord
program
reason
recommend
vaccin
time
hospit
discharg
patient
discharg
patient
hospit
aecopd
hospitalist
consid
need
close
followup
longterm
oxygen
therapi
pulmonari
rehabilit
followup
appoint
schedul
hospit
aecopd
close
outpati
followup
discharg
recommend
popul
patient
approxim
patient
hospit
aecopd
readmit
within
day
although
best
mean
reduc
readmiss
popul
remain
uncertain
one
larg
retrospect
cohort
studi
demonstr
rate
readmiss
lower
patient
attend
followup
visit
either
primari
care
physician
pulmonologist
within
day
discharg
causal
link
followup
appoint
readmiss
deduc
studi
certainli
rais
awar
potenti
benefit
time
followup
appoint
patient
optim
time
followup
aecopd
clear
gold
guidelin
suggest
schedul
week
discharg
patient
continu
requir
oxygen
therapi
maintain
adequ
oxygen
time
discharg
discharg
continu
oxygen
therapi
longterm
oxygen
therapi
shown
reduc
mortal
hospit
patient
sever
hypoxemia
guidelin
american
thorac
societi
european
respiratori
societi
recommend
patient
hypoxemia
treat
longterm
oxygen
therapi
fig
patient
aecopd
often
meet
criteria
longterm
oxygen
therapi
time
hospit
discharg
hospitalist
prescrib
oxygen
case
howev
patient
discharg
home
oxygen
therapi
aecopd
improv
oxygen
recov
acut
ill
abl
eventu
discontinu
oxygen
therapi
reassess
patient
oxygen
statu
one
import
goal
followup
appoint
alreadi
discuss
also
worth
note
patient
use
longterm
oxygen
therapi
chronic
ie
use
time
admiss
gener
continu
therapi
discharg
even
appear
meet
criteria
time
discharg
thought
longterm
oxygen
therapi
may
repar
effect
time
patient
chronic
hypoxemia
lead
augment
oxygen
may
undon
discontinu
oxygen
therapi
hospitalist
refer
patient
pulmonari
rehabilit
program
hospit
aecopd
pulmonari
rehabilit
establish
part
treatment
copd
program
includ
multipl
intervent
might
includ
strength
endur
train
breath
exercis
smoke
cessat
educ
psychosoci
intervent
forth
core
part
treatment
involv
train
muscl
ambul
program
decreas
dyspnea
improv
qualiti
life
decreas
hospit
copd
patient
sever
studi
look
valu
pulmonari
rehabilit
specif
context
aecopd
cochran
collabor
metaanalysi
studi
pulmonari
rehabilit
aecopd
requir
hospit
demonstr
signific
reduct
rate
hospit
death
patient
random
earli
pulmonari
rehabilit
qualityoflif
measur
also
improv
group
studi
start
rehabilit
within
day
discharg
patient
hospit
mean
fev
less
predict
studi
rang
predict
individu
studi
metaanalysi
small
modest
methodolog
qualiti
taken
togeth
find
compel
hospitalist
consid
earli
referr
pulmonari
rehabilit
program
arrang
posthospit
care
patient
aecopd
